23andMe Sale Shows Your Genetic Data Is Worth $17

On Monday, Regeneron acquired bankrupt 23andMe for $256 million, valuing each customer’s genetic data at roughly $17. The pharmaceutical company will take over 23andMe’s genome services and biobank containing DNA from approximately 15 million customers to enhance its drug discovery efforts. Regeneron has committed to maintaining customer privacy policies as the transaction undergoes court review, with closure expected in Q3 2025. This acquisition reflects a significant decrease in genetic data valuation compared to GSK’s 2018 investment that valued similar data at $60 per person.